ArticleInflammation2025
C7ORF41 Alleviates Ferroptosis Via the Keap1/Nrf2/HO-1 Axis in Endotoxin-Associated Acute Kidney Injury.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrating network pharmacology, molecular docking, machine learning, and experimental validation: puerarin improves sepsis-induced acute kidney injury via the Sirt1-Nrf2-HO-1 pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Therapeutic and mechanistic insights on mitochondrial transplantation in kidney disease.Nature reviews. Nephrology · 2026Review
- Azilsartan as a novel anti-ferriptotic agent via the upregulation of the Nrf2/HO-1/SLC7A11/GPX4 axis and downregulation of inflammatory pathways in folic acid-induced acute kidney injury in male mice.Toxicology reports · 2026Article
- Ginsenoside Rb1-engineered nanocomposite hydrogel promotes pressure injury repair through SIRT1-AMPK-mediated ferroptosis inhibition and angiogenesis activation.Journal of ginseng research · 2026Article
- Dexmedetomidine alleviates sepsis-associated acute kidney injury by inhibiting renal tubular ferroptosis via JNK/MAPK-LCN2 pathway.European journal of medical research · 2026Article
- Nrf2 functions as a biomarker and therapeutic target in lung cancer based on bibliometric analysis and molecular mechanisms.Discover oncology · 2025Article
- Haem Oxygenase-1, Ferroptosis and Disorders-A Narrative Review.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Endotoxin-associated acute kidney injury (EA-AKI) is a critical complication in intensive care units. Ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation, has been implicated in EA-AKI; however, its regulatory mechanisms remain unclear. Prior research links C7ORF41 to anti-inflammatory effects and cellular stress regulation. This study aimed to investigate the role of C7ORF41 in EA-AKI and its connection with ferroptosis. We used C7ORF41 knockout (KO) mice and wild-type (WT) mice to evaluate the impact of C7ORF41 on renal function and ferroptosis in an LPS-induced AKI model. Human renal cortical proximal tubular epithelial (HK-2) cells were transfected with C7ORF41 shRNA or control vector to study the role of C7ORF41 in ferroptosis in vitro. We measured serum creatinine (sCr), blood urea nitrogen (BUN), reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH) levels, as well as the expression of ferroptosis-related proteins. C7ORF41 expression was decreased in the kidneys of endotoxemic mice and in LPS-treated HK-2 cells. C7ORF41 deficiency significantly exacerbated LPS-induced lipid peroxidation, tissue damage, and renal dysfunction. In vitro, C7ORF41 knockdown increased ferroptotic cell death, lipid ROS, and decreased GPX4 expression. Mechanistically, C7ORF41 deficiency promotes ferroptosis in EA-AKI through the Keap1/Nrf2/HO-1 axis, highlighting its potential as a therapeutic target for EA-AKI treatment. This study provides new insights into the molecular mechanisms underlying ferroptosis in EA-AKI and offers a potential therapeutic strategy for this severe clinical condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.